Sublingual sufentanil for postoperative pain relief: first clinical experiences
Received 17 December 2017
Accepted for publication 10 April 2018
Published 24 May 2018 Volume 2018:11 Pages 987—992
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 3
Editor who approved publication: Dr Erica Wegrzyn
Fleur Meijer,1 Petra Cornelissen,2 Corina Sie,3 Michel Wagemans,4 Anja Mars,5 Tiny Hobma,1,6 Marieke Niesters,1 Albert Dahan,1 J Seppe Koopman,6 Monique AH Steegers2
1Department of Anesthesiology, Leiden University Medical Centre, Leiden, the Netherlands; 2Department of Anesthesiology Pain and Palliative Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands; 3Department of Anesthesiology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Anesthesiology and Pain Medicine, Reinier de Graaf Hospital, Delft, the Netherlands; 5Department of Anesthesiology and Acute Pain Service, Alrijne Hospital, Leiderdorp, the Netherlands; 6Department of Anesthesiology, Maasstad Hospital, Rotterdam, the Netherlands
Background: The sublingual sufentanil tablet system (SSTS) is a novel hand-held patient-controlled analgesia device developed for treatment of moderate-to-severe postoperative pain. Here we present the first results of its clinical use.
Methods: Adult patients undergoing major surgery in five hospitals in the Netherlands received the SSTS for postoperative pain relief as part of multimodal pain management that further included paracetamol and a nonsteroidal anti-inflammatory drug (NSAID). The following variables were collected: postoperative pain scores using the 11-point numerical rating score (NRS) at rest, number of tablets used, occurrence of nausea, and patient satisfaction scores.
Results: We included 280 patients in the study; the majority underwent laparoscopic abdominal (49%) or orthopedic (knee replacement) surgery (34%). The median NRS was 3.5 (interquartile range 2.3–4.0) on the day of surgery, 3.3 (2.3–4.0) on the first postoperative day, and 2.8 (2.0–4.0) on the second postoperative day; pain scores did not differ between surgery types. Mean number of tablets used was 19 (range 0–86). Nausea occurred in 34% of patients, more often in women (45% vs 19%). Overall satisfaction was high in 73% of patients. Satisfaction was correlated with pain relief (p<0.001) and inversely correlated with occurrence of nausea (p=0.01).
Discussion: In this data set obtained under real-life conditions we show that the SSTS effectively managed postoperative pain in abdominal and orthopedic surgeries. Future studies should determine patient populations that benefit most from the SSTS, assess the added values versus intravenous patient-controlled analgesia, and determine the pharmacoeconomics of the system.
Keywords: acute pain, opioid, postoperative pain, sufentanil, sublingual formulation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]